The Biostatistics Shared Resource ofthe Cancer Center at UCD was established in November 2000, with substantial institutional support, and has facilitated research efforts of the Cancer Center through two funding cycles of the CCSG. The purpose of the Biostatistics Shared Resource is to provide Cancer Center investigators with analytic support for projects internally funded by the Cancer Center and with design support for proposals for externally funded research. The goals ofthe Shared Resource are to: provide statistical expertise for the design of new studies, including sample size and power calculations and analytic plans;provide statistical advice and carry out analyses for research funded within the Cancer Center Programs and other Shared Resources, including pilot studies and quantitative assessment of methodology;foster development of externally funded research on statistical methodology relevant to the research goals of the Cancer Center;provide statistical consultation to the Scientific Review Board and for data monitoring boards;and provide education and mentoring in the biostatistics skills necessary for cancer researchers. The Shared Resource has a strong record of accomplishment during this funding cycle. We have expanded the number of faculty members and staff, collaborated on the design and planning of virtually every new research project in the Cancer Center, co-authored papers in a wide range of cancer-related research, contributed new statistical methodology directly related to cancer, and played a key role in the administration of the Cancer Center. Every clinical protocol receives full statistical review and must have a named statistician. In addition, our faculty members have played an active role in the education mission ofthe Cancer Center, especially in mentoring fellows and junior faculty beginning their research careers in cancer, leading to successful publications and funding for a growing number of our mentees. Our growing role is reflected in the increasing demand for our services and in the success ofthe Center's research mission. Close to half of all biostatistical collaboration in the School of Medicine is cancer-related, reflecting our ability to leverage institutional and CTSA support and our commitment to provide high-quality statistical support.

Public Health Relevance

Biostatistical collaboration is essential for all aspects of cancer research to ensure careful design and analysis of studies. Our resource helps develop the understanding the great variation in cancer and using that understanding to improve treatment, prevention, and care. In addition, it mentors a new generation of cancer researchers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Davis
United States
Zip Code
Braithwaite, Dejana; Miglioretti, Diana L; Zhu, Weiwei et al. (2018) Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med 178:494-501
Unger, Jakob; Sun, Tianchen; Chen, Yi-Ling et al. (2018) Method for accurate registration of tissue autofluorescence imaging data with corresponding histology: a means for enhanced tumor margin assessment. J Biomed Opt 23:1-11
Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004
Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87
Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :
Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529

Showing the most recent 10 out of 836 publications